Avacta Life Sciences Limited
  • About
  • Therapeutics
  • Diagnostics
  • Investors
  • News
  • Careers
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
Home News
filter by: view all | Blogs | Diagnostics | Investors | Therapeutics

News

30 Mar 2022

Notice of Results and Investor Presentation

Investors
29 Mar 2022

Avacta to present pre-clinical data on AVA6000 at the American Association for Cancer Research Annual Meeting

Investors | Therapeutics
21 Mar 2022

Directorate Change

Investors | Therapeutics
16 Mar 2022

Vimian Group acquires Avacta’s Animal Health Division

Investors
03 Feb 2022

Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin

Investors | Therapeutics
19 Jan 2022

‘Diagnosing Emerging Variants of SARS-CoV-2 for Effective Transmission Control’ article published in European Biopharmaceutical Review January 2022

Blogs
18 Jan 2022

Avacta Selects Second pre|CISIONTM Pro-drug Candidate for Development

Investors | Therapeutics
10 Jan 2022

Update on AffiDX® SARS-CoV-2 antigen lateral flow test and detection of the Omicron variant

Diagnostics | Investors
22 Dec 2021

AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing

Diagnostics | Investors
16 Dec 2021

Issue of Equity and Total Voting Rights

Investors

Posts navigation

Older posts
Newer posts
Avacta Life Sciences Limited
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Returns & cancellations policy
  • Corporate Responsibility
  • Contact Us

Avacta Diagnostics

Unit 20, Ash Way
Thorp Arch Estate
Wetherby
LS23 7FA
+44 (0)1904 21 7070

virtual tour
email

Avacta Therapeutics

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

Investor Enquiries

FTI Consulting
200 Aldersgate
Aldersgate Street
London
EC1A 4HD

Email

Twitter | Linkedin

©2022 Avacta Life Sciences Limited. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok